Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy.

Autor: Pe KCS; Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand., Jewmoung S; Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand., Rad SAH; Kite Pharma Inc, Santa Monica, California, USA., Chantarat N; Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand., Chanswangphuwana C; Division of Hematology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Tashiro H; Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan., Suppipat K; Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand; Department of Research Affair, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Thailand Hub of Talents in Cancer Immunotherapy (TTCI), Bangkok, Thailand., Tawinwung S; Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand; Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand; Thailand Hub of Talents in Cancer Immunotherapy (TTCI), Bangkok, Thailand. Electronic address: supannikar.t@pharm.chula.ac.th.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Oct; Vol. 179, pp. 117388. Date of Electronic Publication: 2024 Sep 08.